299 related articles for article (PubMed ID: 32473614)
1. Potential dual functional roles of the Y-linked RBMY in hepatocarcinogenesis.
Kido T; Tabatabai ZL; Chen X; Lau YC
Cancer Sci; 2020 Aug; 111(8):2987-2999. PubMed ID: 32473614
[TBL] [Abstract][Full Text] [Related]
2. Male germ cell-specific RNA binding protein RBMY: a new oncogene explaining male predominance in liver cancer.
Tsuei DJ; Lee PH; Peng HY; Lu HL; Su DS; Jeng YM; Hsu HC; Hsu SH; Wu JF; Ni YH; Chang MH
PLoS One; 2011; 6(11):e26948. PubMed ID: 22073224
[TBL] [Abstract][Full Text] [Related]
3. RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.
Chua HH; Tsuei DJ; Lee PH; Jeng YM; Lu J; Wu JF; Su DS; Chen YH; Chien CS; Kao PC; Lee CN; Hu RH; Ni YH; Chang MH
Hepatology; 2015 Nov; 62(5):1480-96. PubMed ID: 26185016
[TBL] [Abstract][Full Text] [Related]
4. PIM1-Induced Cytoplasmic Expression of RBMY Mediates Hepatocellular Carcinoma Metastasis.
Chua HH; Chang MH; Chen YH; Tsuei DJ; Jeng YM; Lee PH; Ni YH
Cell Mol Gastroenterol Hepatol; 2023; 15(1):121-152. PubMed ID: 36191855
[TBL] [Abstract][Full Text] [Related]
5. ANP32A promotes the proliferation, migration and invasion of hepatocellular carcinoma by modulating the HMGA1/STAT3 pathway.
Tian Z; Liu Z; Fang X; Cao K; Zhang B; Wu R; Wen X; Wen Q; Shi H; Wang R
Carcinogenesis; 2021 Apr; 42(3):493-506. PubMed ID: 33332531
[TBL] [Abstract][Full Text] [Related]
6. RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts.
Tsuei DJ; Hsu HC; Lee PH; Jeng YM; Pu YS; Chen CN; Lee YC; Chou WC; Chang CJ; Ni YH; Chang MH
Oncogene; 2004 Jul; 23(34):5815-22. PubMed ID: 15184870
[TBL] [Abstract][Full Text] [Related]
7. Oncogene-dependent function of BRG1 in hepatocarcinogenesis.
Wang P; Song X; Cao D; Cui K; Wang J; Utpatel K; Shang R; Wang H; Che L; Evert M; Zhao K; Calvisi DF; Chen X
Cell Death Dis; 2020 Feb; 11(2):91. PubMed ID: 32019910
[TBL] [Abstract][Full Text] [Related]
8. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
9. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
10. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
[TBL] [Abstract][Full Text] [Related]
11. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF
Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794
[TBL] [Abstract][Full Text] [Related]
12. Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy.
Dolicka D; Sobolewski C; Gjorgjieva M; Correia de Sousa M; Berthou F; De Vito C; Colin DJ; Bejuy O; Fournier M; Maeder C; Blackshear PJ; Rubbia-Brandt L; Foti M
Cell Mol Gastroenterol Hepatol; 2021; 11(2):597-621. PubMed ID: 32987153
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.
Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S
BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134
[TBL] [Abstract][Full Text] [Related]
14. Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma.
Zhang Y; Zhang J; Chen X; Yang Z
Int J Med Sci; 2021; 18(2):364-371. PubMed ID: 33390805
[No Abstract] [Full Text] [Related]
15. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.
Zahid KR; Han S; Zhou F; Raza U
Cell Oncol (Dordr); 2019 Feb; 42(1):55-66. PubMed ID: 30238408
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
Wang TH; Yu CC; Lin YS; Chen TC; Yeh CT; Liang KH; Shieh TM; Chen CY; Hsueh C
Oncotarget; 2016 Jul; 7(28):43588-43603. PubMed ID: 27248828
[TBL] [Abstract][Full Text] [Related]
17. LncRNA NEAT1 Promotes Deterioration of Hepatocellular Carcinoma Based on In Vitro Experiments, Data Mining, and RT-qPCR Analysis.
Ling ZA; Xiong DD; Meng RM; Cen JM; Zhao N; Chen G; Li RL; Dang YW
Cell Physiol Biochem; 2018; 48(2):540-555. PubMed ID: 30021196
[TBL] [Abstract][Full Text] [Related]
18. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
[TBL] [Abstract][Full Text] [Related]
19. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
